Veracyte, Inc.
VCYT
Rang in aandelen
#4357
Veracyte, Inc. operates as a diagnostics company in the United States and... Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Aandeelprijs
$44.93
Laatst gesynchroniseerd: 2026-10-20
Marktkapitalisatie
$3.61B
Verandering (1 dag)
2.57%
Verandering (1 jaar)
24.45%
Land
US
Handel Veracyte, Inc. (VCYT)
Categorie
Healthcare
P/S-ratio voor Veracyte, Inc. (VCYT)
P/S-ratio op October 2026 TTM: 6.22
Volgens de meest recente financiële rapporten en aandelenkoers van Veracyte, Inc. is de huidige P/S-ratio (TTM) 6.22. Eind 2023 had het bedrijf een P/S-ratio van 5.54.
P/S-ratiohistoriek voor Veracyte, Inc. van 2011 tot 2026
P/S-ratio aan het einde van elk jaar
| Jaar | P/S-ratio | Wijzigen |
|---|---|---|
| 2026 (TTM) | 6.22 | -8.32% |
| 2024 | 6.79 | 22.75% |
| 2023 | 5.54 | -3.33% |
| 2022 | 5.73 | -55.07% |
| 2021 | 12.74 | -42.55% |
| 2020 | 22.18 | 107.23% |
| 2019 | 10.70 | 111.43% |
| 2018 | 5.06 | 64.40% |
| 2017 | 3.08 | -10.20% |
| 2016 | 3.43 | -9.14% |
| 2015 | 3.77 | -31.06% |
| 2014 | 5.47 | 98.64% |
| 2013 | 2.76 | -82.96% |
| 2012 | 16.18 | -77.25% |
| 2011 | 71.11 | 0.00% |
P/S-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/S-ratio | Verschil in P/S-ratio | Land |
|---|---|---|---|
| 5.37 | -13.70% |
US
|
|
| 6.29 | 1.08% |
US
|
|
| 21.02 | 237.66% |
US
|
|
| - | - |
CN
|
|
| 6.67 | 7.09% |
US
|
